Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On May9, 2017, Aquinox Pharmaceuticals, Inc. (the Company) issued
a press release announcing financial results for the first
quarter ended March31, 2017. The full text of the press release
announcing such results is attached as Exhibit99.1 to this
Current Report on Form 8-K and is incorporated herein
by reference.
The information in
this current report on Form 8-K and the press release
attached as Exhibit 99.1 hereto is being furnished, but shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (Exchange Act), and is not
incorporated by reference into any filing of the Company under
the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits
|
Number |
Description |
|
| 99.1 |
Press Release of Aquinox Pharmaceuticals, Inc. dated May9, 2017 |
About Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Recent Trading Information
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) closed its last trading session down -0.27 at 13.74 with 164,589 shares trading hands.